Nature Reviews Drug Discovery (2020) https://doi.org/10.1038/s41573-020-0073-9 Published online 29 July 2020
In the section ‘Radionuclides used for RPT’, the sentence describing the properties of lutetium-177 has been corrected to “Lutetium-177 gained popularity because it emits photons in the 100–200-keV optimal imaging range and has a β-particle energy appropriate for therapy.” This correction has been made to the online version of the review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sgouros, G., Bodei, L., McDevitt, M.R. et al. Author Correction: Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov 19, 819 (2020). https://doi.org/10.1038/s41573-020-0085-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41573-020-0085-5
